Clinical Trial Update: COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-masked COMO trial is recruiting to compare EYP-1901 with aflibercept for diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)
• EYP-1901

Snippet

Sponsor: EyePoint Pharmaceuticals, Inc. | Conditions: Diabetic Macular Edema, DME | Phase 3 | Status: RECRUITING